FMP
EURONEXT
0.107 EUR
0.0034 (3.17%)
Dr. Jean-Philippe Milon Ph.D.
Healthcare
Biotechnology
https://www.quantum-genomics.com
EURONEXT
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
N/A
FR0011648971
F76288111
33 rue Marbeuf
33 1 85 34 77 70
FR
3
May 28, 2010
-
EURONEXT
Biotechnology
Healthcare
F76288111
FR0011648971
FR
0.11
0.71
111.09k
3.7M
-
0.0804-0.212
0
-
-
-
-
-0.13
-
https://www.quantum-genomics.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.